Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
BOTHELL, Wash., March 06, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab (formerly ALD403), which is in clinical development for the prevention of migraine, will be presented at the upcoming 69th Annual American Academy of Neurology meeting on April 22-28, 2017 in Boston.
- Platform presentation: Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine
Session: S52, Headache: Clinical Trials and Disease Burden
Date: Friday, April 28, 2017
Presenter: Dr. David Dodick
Time: 1:24 p.m.
Location: Boston Convention and Exhibition Center
- Poster presentation: Rational Design of a Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of Migraine
Poster: #155
Date: Monday, April 24
Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
Location: Boston Convention and Exhibition Center, Poster Session II
- Poster presentation: 75% Responder Rates Provide Improvement in HIT-6 Scores from Week 4 Through 12 Following a Single Infusion of ALD403, or Placebo
Poster: #165
Date: Monday, April 24
Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
Location: Boston Convention and Exhibition Center, Poster Session II
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Victoria Meissner Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals Inc. (425) 408-8032 [email protected]
